SCHEMBL25822329

SCHEMBL25822329

O=C(Nc1cc(Oc2ccccc2)ccn1)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.62
FFAR1 O14842 1/20 0.60
LMNA P02545 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.56
GRM5 P41594 4/20 0.55
PYGL P06737 2/20 0.55
PYGM P11217 2/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
ALDH1A1 P00352 1/20 0.54
GCK P35557 1/20 0.54
BRAF P15056 1/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822252 0.93 SMN1; SMN2 (0.60) MAPTFFAR1LMNASMN1; SMN2KMT2A
SCHEMBL25822301 0.89 KMT2A (0.57) MAPTLMNASMN1; SMN2KMT2AMEN1
SCHEMBL24011034 0.81 GRM5 (0.59) MAPTSMN1; SMN2KMT2AMEN1GRM5
SCHEMBL31315570 0.81 FFAR1 (0.80) MAPTFFAR1LMNASMN1; SMN2KMT2A
SCHEMBL27676573 0.81 FFAR1 (0.80) MAPTFFAR1LMNASMN1; SMN2KMT2A
SCHEMBL25821902 0.81 LMNA (0.70) MAPTFFAR1LMNASMN1; SMN2KMT2A
SCHEMBL10090737 0.81 ALDH1A1 (0.78) LMNASMN1; SMN2KMT2AMEN1NPC1
SCHEMBL25822054 0.80 KMT2A (0.66) MAPTLMNASMN1; SMN2KMT2AMEN1
SCHEMBL4330869 0.79 GCK (0.55) MAPTFFAR1SMN1; SMN2KMT2AMEN1
SCHEMBL2272594 0.78 PYGL (0.72) MAPTFFAR1KMT2AMEN1PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA MAPT 3976/4885FFAR1 1339/4885LMNA 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.